Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks for your post. Please elaborate. The msg is too cryptic to decipher.
I don't believe so, but who knows.
He's had 4 residences in the USA he's claimed over the past 6 years.
One was in Colorado, Three are in Texas (Katy, CC's house and one near Austin)
He has a lot of family over in India and in Katy, TX.
I've heard the S. Africa home 3 times from investors, never from him.
His cell phone was bought in the Greater Denver, CO area. (for US use, anyhow).
I don't know where he actually hangs his hat, but I get the feeling he moves about and stays long in a lot of different places.
Terry
The quarterlies and annual reports claim Cape Town, South Africa.
https://www.otcmarkets.com/stock/ENZC/disclosure
His recent trademark application shows Katy, Texas.
https://uspto.report/company/Chandra-Gaurav
His LinkedIn shows Denver, Colorado.
https://www.linkedin.com/in/gaurav-chandra-a8964b74
There are probably other locations that he claims as home on other social media sites. Where in the world is Chandra?
I. Wish. I . Could. Decode. Your. Message.
Where did you read he is coming back to the US? Isn’t he living in South Africa?
1-Out.Secret.-When.An.AttorneyCEO..deal.made.+ A..Default.Clause.to.dissolve.contract.
This could explain cool attitude..at the top
I see Chandra's done in India today, about to head back to the states. Hope he feels like disclosing something more meaty when he gets back.
Yeah, putting all of these in chronological order and then by defendant name and date is like a puzzle these days. Summary judgement for running from the case and never responding to it, sounds right for Kostiner. Remember, his other earlier case, he did the same thing. Does not matter who seizes SAGALIAM assets though.
At the time of 'seizing', ENZC is a named asset of SAGA, unless all of the ENZC posts about that are lies too, knowingly pushed out to try and spike share sales. ENZC, if the posted stories are true about the original agreement being honored, leaves them about to be frozen in their tracks. What can a poor Sharabura do?
Those idiots. From all legalities and posts from last year, ENZC is not currently owned by SAGA, and they may have to say so in a case response. If not, they're about to be frozen, if so, then Sharabura can keep on posting BS, and ENZC worms away from SAGA as if they don't even know who they are anymore. There's another case pending against Kostiner too, good luck SAGA moron(s).
Hey Savov, Harry is saying your mother sews boxers that smell. You need to come to Texas and make HZ disappear!
GLTA
Thanks SS, checking now, will probably take a while. KoP blocked me on X, and I got tired of paying the current records release fee(s).
GLTA
Completely agree. Although tempting, I'd best not try to accumulate more now. Too bad, I was about to top off my million shares, see what happens.
This Would.be then encouraging and good
docsetc, My understanding is that as many as 12 different brokerages shut down access to trading accounts yesterday. “Coincidence” ??? I think not.
Since I don't use twitter, I'm not sure if I have the correct case (I think I do). I did find this after a little more digging: "https://www.bloomberglaw.com/public/desktop/document/MayerBrownvSagaliamAcquisitionCorpetalDocketNoN24C05097DelSuperCt?doc_id=X1Q6OMKB2BO2"
which appears to show two additional filings that appear to be judgements on the praecipe for writ of attachments. I don't have an account with bloomberglaw.com so I cannot see what they filed. These are filings that I believe are in addition to the case I referenced earlier. I'm unclear as to whether a "Judgment" in this case has been declared. I also want to point out that the link I provided here is different than the one I referenced earlier (that I believe to be the twitter link).
Barry does not seem to have a lot of respect for the legal system.
If Harry "has beaucoup PIPE money lined up for SAGA" then ENZC and SAGA would not be in the situation they are currently in. ENZC and SAGA will not recognize that the deal never closed until the court tells them so. SAGA paid a $20,000 nonrefundable fee to contest their Nasdaq delisting (which they should have known that they would lose). I'm guessing they did this just to buy time. In the meantime they will continue to sell shares (notice the recent Authorized Share increase). I also think that the SAGA purchase from ENZC was a facade, and never really completed. I'm not sure if the parties involved understand that this was not a valid transaction. Thanks for using the word beaucoup, haven't seen or heard that one in a while.
I'm not a lawyer either, but my best guess is that you've got the right case. JMHO.
I'm assuming most of Mayer Brown's legal fees were in respect to SAGA's failed attempt to close on the Saudi deal, which preceded ENZC's discussions with SAGA. It appears to me that SAGA never responded to the lawsuit, didn't hire a defense lawyer or appear in the case, so the Plaintiff asked for a default judgment and may have gotten it. The status of the case in the heading of the docket report says: "Judgment". Interesting strategy (?).
JMHO...I would say that unless Harry has beaucoup PIPE money lined up for SAGA, this is a good time to give up the "facade" (if that's what it really is) and recognize that SAGA failed to pay its renewals last fall and the deal with ENZC never closed.
If I'm not mistaken, GLD got default judgments against Kelli Austin and BN Holdings for its purchase of the SAGA Sponsor shares, too.
👍— funny as well
I am only guessing that this is the case being referred to. I could be incorrect, and it may me a completely different case being referenced (the players involved here are involved in quite a few legal cases). For all I know there could be another case that I am unaware of that has been decided in favor of the former lawyers for "SAGALIAM SPONSOR LLC and SAGALIAM ACQUISITION CORP." I am not a "legal professional", so I only have access to a limited amount of information. The way that I am reading what I see is that it is only a request for a Praecipe for Writ of Attachment, but I could be incorrect.
https://delcode.delaware.gov/title10/c035/index.html#:~:text=A%20writ%20of%20domestic%20attachment%20may%20be%20issued,his%20or%20her%20creditors%20or%20to%20elude%20process.
If there are any "legal professionals" out there reading this, please feel free to correct anything I have incorrectly stated.
SS..It's.impt.to.know.this.entire.writ.issue.after reading.shows.its.for a.request..only
Is the case you were trying to provide the link for (MAYER BROWN V. SAGALIAM ACQUISITION CORP. ET AL):
https://courtconnect.courts.delaware.gov/cc/cconnect/ck_public_qry_doct.cp_dktrpt_frames?backto=P&case_id=N24C-05-097
I'm only guessing because I don't use twitter, and what you provided was really incomplete.
Noticed.._buying.is.progressing..bc..they.work.all.things.out..and.we.find.out Add to it..being and talking positive and watching them get everything done is what we can do as some are getting a chance at being buyers at entry level prices.
Maybe so, but that latest news about SAGA's old lawyers winning a $2 million dollar case against SAGALIAM, and seizing assets, could spell doom for this stock. I hope not, but could be.
GLTY!
Current.bids looks,steady, with.dip''buys.and.buys,,something..is.known
PffFFAHH!.... Think or Swim is down again. Back over to ETrade!
That's fantastic actually, thanks Wick!
It couldn't have happened to a nicer bunch of folks. That explains some of the folks trying to dump their ENZC shares and got a notice from their brokers warning of a delayed settlement of funds on the sale. I've had two such people private-message me their brokerage page screenshots.
It will be a major sticking point for Harry Zhabilov, if he can't sever ENZC from SAGA and those writs, he's cooked once and for all. He does however, with the old Sagaliam Agreement, have legal points for worming out of the Attorney writs, and leaving Kostiner holding the bag for everything.
However, those attorneys may know some things about how closely Kostiner and Zhabilov were conducting BS business that we only suspected. Could be Zhabilov signed his own company death warrant by actually operating as part of Sagaliam. ENZC could be frozen any day now.
Funnier still, to get out of this mess, Harry would have to publicly show SAGA is dead and the partnership never legally consummated, meaning SAGA never owned or owns ENZC. Because, ENZC, debtor as it is, would be defined as an "asset of Sagaliam Corp".
Shares would have to be returned, and CCC gets voting control. Otherwise, Harry goes down and out, painfully, with this collection by the SAGA attorneys.
CCC can now decide upon a one-time share conversion price for ENZC shareholders, or try to wait it out, if Harry can get out of the legal action against SAGA. (Take over from there). In any case, I'm betting the go-public date for Adnexus us held up for further developments on this attorney collection action against Kostiner. Seizing assets of SAGA and ENZC, no laughing matter.
Man, just a few fools in OTC:PINK land can sure create a lot of ridiculous drama.... Say hi to Madoff in Hell for me Harry.
docserc, From King of Prussia X account: “$ENZC The former attorneys for Sagaliam Acquisition Corp. and Sagaliam Sponsor LLC have issued Writs of Attachment against both entities as of yesterday.
They sued the SAGA entities for $2,000,000 in unpaid legal fees and won. Now they want their money.
Don't worry. I'm sure the dividend is right around the corner. 🙉🙈🙊
Link: courtconnect.courts.delaware.gov/cc/cconnect/c “
Hope this is the post you are referring to…
Definitely keep holding on to this on TJ, this guarantees you get something out of CC eventually, unless they sell of their new companies for $1.00, something ludicrous like that.
The legal linkage from BioClonetics and ENZC was voluntarily spelled out for you by CC himself, and legally, he and Chandra left voluntarily from ENZC to protect their IP's which they've now assigned to another company they also own (as they were part owners of ENZC too). Legally, what I've been calling 'shared liability' is still there on the CCC gang, even if Harry Zhabilov was 100% the bad guy. They (CCC) did publicly endorse the SAGA deal, the proposed subs, and IP assignments etc.. so most judges and legal statutes would continue to hold their feet to the fire.
My best advice after reading this one is bide your time, manage some patience. Either they come up with an ENZC solution, or they face legal messes that someone will start up soon enough.
The one reason I believe that CCC does have a remedy plan in place, (?) no matter what their ownership skills are, they're not stupid and they have to know they've got loaded barrels aimed at their backs if Clone3/7 ever become successful in the new companies, and they left over a 1000 investors holding a bag still connected to them by legal umbilical cords.
GLTY
DANG! I mentioned to Chandra about the widespread web-chatter about folks trying to set up a class-action against ENZC. (on Twitter/X) Suddenly, I have a couple hundred new followers. (Most of them sound a lot angrier than folks on this board do.)
That was not intended. I was trying to convey to Chandra, that if they have an ENZC shareholder remedy or remedy plan, he needs to whisper the word out to avoid more potential trouble in the coming winds. If they do come up with an ENZC shareholder remedy, of most any sort, I'd hate to see it all get bogged down in some form of class-action pursuit.
If I have not been clear here: I do support the public launch of Adnexus Biotech and possibly MABS-Tech too, and what CCC seems to be trying to do. (I know the downside risks, yes...)
If they don't come up with a reasonable ENZC solution, then I'll be quickly reassessing my options. I hope most here feel the same, but after this SNAFU of a PINK:OTC stock, any opinion is justified. Liars can go to heck, but thoughtful opinions are always respected, by me anyhow.
Theo James sent me a copy of a recent Twitter/X post. It referenced a post on KoP's page, describing SAGA getting assets seized. I had no details on this post and I could not use the link to go back and check it out. Maybe someone else can? I don't know if it's some old post reposted, or if this was a new update.
I can't check it myself, since KoP blocked me for challenging his opinion that the SAGA deal was going to be a great success for ENZC. I would have been happy to discuss it with him, but wusses block-n-hide, that is nature of pumpers too. If anyone else saw it, let me know what you think please. I've asked Theo to post that publicly here.
Thanks TJ, good stuff there, hope this works out for you.
My brother ran the numbers and legal logistics, so to speak. He examined the dilution of share value over the past couple of years, and pointed out that your current investment return, if the company was declared profitable today, would barely pay you back stock or cash worth that original $200.00 investment, legally, nowhere else to go besides barely getting your money back, unless CC promised more than a 10:1 return in shares for your startup investment.
He also agreed, there would be a serious case of defrauded investors if say 10 of you came forward with those start-up investment promissory notes. Merging the company in left your notes intact, and then, what would legally be CCC moving their IP's to new companies post-haste, and starting up again, leaves them at high-risk to both you as startup investors, and to the common shareholders too, by way of other types of potential fraud counts.
But he repeated his warning, that your investment is so low, and this is OTC:Pink land, it would take a very good and interested attorney to file on them, Charles in particular, looking to claim his assets to pay you back your money and damages for fraudulent promises and behavior. And because its Pink Land, and most small claims judges don't know squat about finance or investment (SEC) rules, regulations and standards, Charles could delay it for some time, trying to run out the clock on you. (Which my brother says is easy in this situation.)
His best advice was to stand pat, see where Charles and Chandra start this thing back up, then make an official overture to Cotropia, asking him to honor his previously signed agreement. My brother also reminded me, you need to have the canceled check, receipt, bank statement, whatever it is you had to prove both the promissory note and the payment actually took place.
I know, I know, stating the obvious but after reading the board off of my account, and me bringing him up to speed, he's aware how inflamed everyone's feelings are on this matter. He also said the advice I gave to you in reaching out to Charles first, with a hint of legal action if he does not work with you to get you settled first, is probably the best course of action. He advised me to do the same in a common shareholder fashion.
I'm traveling right now on my company laptop, and I had/have CCC's home address in Texas on the other laptop. I'll try to send that over to you. Several other folks on this board have posted his address before, might want to look over the last 30'days messages too.
It's here.
GLTY
Thanks docsetc keeping the information flowing. Appreciate it.
Thanks for the updates Doc.
Thanks Doc you make some great points .We need you to keep us informed ,I think CCC only repond to legal challenges and will not do anything out of generosity. They are not to be trusted ever.
On 12/22/2020, I sent to Charles the following email:
-------------------------------------------------------------
Hello, Mr. Cotropia.
Thank you for your recent updates.
I am confused about something.
I have a SAFE (Simple Agreement for Future Equity) with Bioclonetics that I purchased via Wefunder. I have attached the SAFE to this email.
That SAFE went into effect on 11/3/17 and has a valuation cap of $6,000,000.
On page 3 of the SAFE, the term "Change of Control" is defined. My understanding is that Enzolytics's acquisition of Bioclonetics qualifies as a "Change of Control" of Bioclonetics.
On page 4 of the SAFE, the term "Liquidity Event" is defined as a "Change of Control" or an "Initial Public Offering". So, my understanding is that Enzolytics's acquisition of Bioclonetics qualifies as a "Liquidity Event".
On page 1 of the SAFE, Section 1(b) states the following:
If there is a Liquidity Event before the expiration or termination of this instrument, the Investor will, at its option, either (i) receive a cash payment equal to the Purchase Amount (subject to the following paragraph) or (ii) automatically receive from the Company a number of shares of Common Stock equal to the Purchase Amount divided by the Liquidity Price, if the Investor fails to select the cash option.
So, if Enzolytics's acquisition of Bioclonetics is a "Liquidity Event", then aren't I entitled to receive Bioclonetics Common Stock right now?
Why would I have to wait until Enzolytics is acquired?
If Enzolytics's acquisition of Bioclonetics is not a "Liquidity Event", please explain why that is.
Also, regarding investor option 3, Enzolytics stock is an OTC stock. There are online articles that warn people to stay away from OTC stocks. The following article is one such article:
https://www.kiplinger.com/article/investing/t048-c008-s001-penny-stocks-why-you-should-always-stay-away.html
Will Enzolytics stock ever "graduate" from OTC status and be sold on a major stock exchange?
-------------------------------------------------------------
Before Charles had a chance to respond to me, I posted some or all of the above email to the BioClonetics Investors Facebook group.
On 12/24/2020, Charles sent the following email to me:
-------------------------------------------------------------
Thank you for being an investor and for your question regarding the effect of the acquisition of BioClonetics by Enzolytics. You are right that the SAFE Note provides that “If there is a Liquidity Event before the expiration or termination of this instrument, the Investor will, …… (ii) automatically receive from the Company a number of shares of Common Stock equal to the Purchase Amount divided by the Liquidity Price, ….
Thus, for there to have been a “Liquidity Event” there must be (by the definitions in the SAFE Note), either a “ Change of Control or an Initial Public Offering.”
Since there has not been a Public Offering, then for there to be a “Liquidity Event” there must have been a “Change of Control”.
In the acquisition, we purposefully arranged the transaction such that upon the acquisition of BioClonetics shares by Enzolytics, and contemporaneously therewith, there was not a change of control in that the shareholders of BioClonetics took and have control of Enzolytics. Thus, we do not consider the acquisition to constitute a “Change of Control”.
Also note that Enzolytics assumed all the crowdfunding obligations of BioClonetics.
One would also want to consider the effect if the deal was interpreted as presenting a Change of Control. If this were the interpretation, one would then need to calculate what is provided by the Note language, namely “automatically receive from the Company a number of shares of Common Stock equal to the Purchase Amount divided by the Liquidity Price”.
It appears that a BioClonetics shareholder would be entitled to a “Number of shares” in BioClonetics calculated as follows:
Number of shares = Purchase price ($200) / Liquidity Price
The Note defines Liquidity Price as:
“Liquidity Price” means the price per share equal to the Valuation Cap ($6,000,000) divided by the Liquidity Capitalization.
“Liquidity Capitalization” means the number, as of immediately prior to the Liquidity Event, of shares of Capital Stock (on an as-converted basis) outstanding, assuming exercise or conversion of all outstanding vested and unvested options, warrants and other convertible securities, but excluding: (i) shares of Common Stock reserved and available for future grant under any equity incentive or similar plan; (ii) this instrument; (iii) other Safes; and (iv) convertible promissory notes.
As I interpret this language, the Number of Shares one would be entitled to is:
Number of shares = $200/[($6,0000,000/number of shares of Capital Stock in BioClonetics)] = 0.000033333333 X number of shares of Capital Stock in BioClonetics.
BioClonetics has 31,500 Capital Stock shares.
Thus, you would be entitled to 0.000033333333 X 31,500 = 1.05 share.
Even if this were an option, I don’t see how this would be better than any of the 3 Options we have offered. All of the 3 offered Options have a road to some value in the future.
Owning 1.05 share of BioClonetics (at least as I see it) would not have a similar road to value.
I hope this conveys how we interpret the present situation.
After giving this some thought (and noticing that you did not await our response before posting your question on our Facebook site), I question your motive. Why not try to assist our bonafide efforts to help provide desperately needed therapeutic cures to serious pandemics – rather than go to the other side?
Best regards,
Charles
Charles Cotropia
Enzolytics
-------------------------------------------------------------
In mid-January 2021, I chose to convert my BioClonetics SAFE into an ENZC SAFE.
Charles's next update was the following email (dated 12/11/2020):
------------------------------------------------------------------
Dear BioClonetics Investors,
We thank each of you for your investment in and continued support of BioClonetics. We are pleased to report that a business combination with Enzolytics Inc. has now been completed. In this combination, Enzolytics has acquired BioClonetics resulting in the merger of the BioClonetics’ technology for producing fully human monoclonal antibodies against infectious diseases (including HIV and the Coronavirus) with Enzolytics’ patented and clinically tested anti-HIV therapeutic. This correspondence is intended to report the effect of that acquisition on your investment in BioClonetics.
First, we believe the two therapies of our Companies will be synergistic and are moving forward to further develop them independently and as a combined therapy. Thus, we believe the combination of technologies brings great value to our investors.
The crowdfunding raise in which you invested was through a convertible note called a SAFE (a Simple Agreement for Future Equity). A SAFE is an agreement between investors and the Company that provides rights to the investor for future equity in the company similar to a warrant, except without determining a specific price per share at the time of the initial investment. The SAFE investor receives the futures shares when a priced round of investment or acquisition occurs. In the acquisition of BioClonetics by Enzolytics, Enzolytics assumed the obligation of BioClonetics to each crowdfunding investor. No event occurred that resulted in an obligation to issue shares. However, we nonetheless are offering each investor the following options and ask that each investor review these with their financial advisor and give us your decision and election by January 15, 2021. If no election is made, the investor will still hold the convertible notes originally issued until such time as a conversion event occurs.
The following 3 options are offered and available to each of our investors:
Option 1:
You may hold your convertible note until a conversion event occurs, namely there is a future Series A financing round or where Enzolytics is acquired. At the end of this report, I have summarized when such a conversion event would occur and how the investor’s investment would be impacted.
Option 2:
In the Startengine Convertible Notes, the Notes provided that the principal investment would be repaid at this time with 2% annual interest. We will honor that obligation to any Startengine investor wishing to elect this option. Should any Wefunder investor wish to elect this option, we would also honor such election.
Option 3:
Because some investors may wish an option whereby they would own shares in Enzolytics (currently traded on as an OTC stock as ENZC), we offer the following option: Holders of the crowdfunding SAFE Notes will be offered a debt exchange for new Preferred Series D shares at a dollar value premium that converts into Common Shares of ENZC one year from the date of exchange. The company is currently developing the terms and designations of the Series D shares that will be distributed to the holders and the specific terms and designations regarding this option will be reported to all investors by December 21.
SUMMARY OF THE OPERATION OF A CONVERTIBLE NOTE ISSUED IN CROWDFUNDING
For purposes of considering Option 1, we provide this general information. Please consult your financial advisor for further information. In our case, convertible notes (a SAFE) were issued to each investor with a valuation CAP of $15 Million (in some cases the valuation CAP provided was $10M). This CAP offers the possibility for appreciation in the following way.
The CAP is a ceiling on the value of our Company (i.e., a maximum dollar amount) for purposes of determining the conversion price of the note at the time of a later Series A round of funding — meaning that in a future Series A financing where financing is provided by an outside source in exchange for shares in our company, if the pre-investment valuation of our company is higher than the CAP, a note holder (you) would receive a proportionally larger number of shares than the later investor. For example, if in a Series A investment, our company were valued at $30M, a SAFE Note investor would receive twice the number of shares issued to the later investor ($30M/$15M = 2 times). And, if the Company is valued even higher at the time of a Series A financing, the SAFE note investor would be issued proportionally more shares. Also, if the Company is acquired, the initial investor’s investment would appreciate proportionally with the acquisition price as compared to the CAP - meaning if the Company were acquired for $30M, then an investment would double and so forth.
We will notify you by December 21 of the additional information needed for you to fully consider Option 3 and we look forward to receiving your election thereafter by January 15, 2021. If no election is made by January 15, 2021, then your investment will remain within the convertible note originally issued to you.
For those wishing to read more about our focus, I was recently interviewed by the CEOCFO Magazine and that interview can be viewed here: https://www.ceocfointerviews.com/enzolytics20.html
Sincerely,
Charles
Charles Cotropia
CEO Enzolytics/BioClonetics
Copyright © 2020 BioClonetics Immunotherapeutics, Inc., All rights reserved.
You are receiving this email because you opted in via our website.
Our mailing address is:
BioClonetics Immunotherapeutics, Inc.
2021 McKinney Ave.
Suite 2000
Dallas, TX 75201
------------------------------------------------------------------
On 12/21/2020, Charles sent the following update:
------------------------------------------------------------------
December 21, 2020
Dear Investors,
We extend our best wishes to you all for a Happy and Healthy Holiday Season.
This is in followup to my earlier report of December 11, 2020, wherein we announced that the Company is offering BioClonetics’ investors 3 Options as set forth in that report (copied below) and restated here with further details regarding Option 3. The Options offered are:
Option 1:
You may hold your convertible note until a conversion event occurs, namely there is a future Series A financing round or where Enzolytics is acquired. At the end of my earlier report, I have summarized when such a conversion event would occur and how the investor’s investment would be impacted.
Option 2:
In the Startengine Convertible Notes, the Notes provided that the principal investment would be repaid at this time with 2% annual interest. We will honor that obligation to any Startengine investor wishing to elect this option. Should any Wefunder investor wish to elect this option, we would also honor such election. If you make this election, please provide me with the mailing address to which you wish these funds to be sent.
Option 3:
Because some investors may wish an option whereby they would own shares in Enzolytics (currently traded on as an OTC stock as ENZC), we offer the following option:
Holders of the crowdfunding Notes are offered a debt exchange for Preferred D Series shares (in the process of being established) that will convert into ENZC Common Shares one year from the date of exchange. In this Option, an investor would exchange $5.00 of debt for one share of Preferred Series D shares. The series D shares will convert into 120 shares of common Enzolytics stock (ENZC) at one year from issuance. This means that at one year from issuance, every $5.00 of investment will ultimately convert into 120 shares of Enzolytics (ENZC) Common Stock.
Please review these options with your financial advisor and provide me with your election by email to csc@bioclonetics.com by January 15, 2021. If you elect Option 2, please provide me with the mailing address to which you request funds be sent.
We ask that each investor review these Options with their financial advisor and give us your decision and election by January 15, 2021. The election offer will only be open until January 15, 2021. If no election is received by that date, the investor will still hold the convertible notes originally issued until such time as a conversion event occurs.
As always, we sincerely thank you for support and your investment in us and in our technology.
Best regards,
Charles
Charles Cotropia
csc@biocloentics.com
CEO Enzolytics/BioClonetics
------------------------------------------------------------------
Doc, since you brought up Charles's statements regarding the ENZC-BioClonetics merger, I think it would be a good idea for me to share with this board Charles's statements on the merger and the emails we exchanged on the merger. My sharing this stuff may take a few posts.
First of all, the following is Charles's first email on the merger (dated 10/20/2020):
-------------------------------------------------------------
Dear Investors and Supporters,
In these trying times caused by the CoronaVirus pandemic, we sincerely hope all of you are doing well. We all look to a brighter future. We have been continuously engaged as a part of the effort to address this health crisis and we appreciate all of your support making our ongoing efforts possible.
We have conferred for some time with Enzolytics, Inc., (OTC PK: ENZC) a public company with a therapeutic that has been successfully tested in patients with HIV and have now entered into an agreement with Enzolytics to combine our technologies to more comprehensively address the HIV pandemic.
This combination of our technologies is underway but will take some time due to the intricacies of the process. We do not have a date for completion of this process but will keep our investors informed as the process progresses.
All of our steps are taken with two objectives in mind. First our focus is on creating successful therapeutics against infectious diseases, including HIV and now our focus on the CoronaVirus. Secondly, our efforts are also intended to increase the value of our technology and the value of our company - which directly translates into value for our investors. Please know that these are our two guiding objectives with every effort we make.
Enzolytics is a drug development company focusing on the commercialization of its proprietary proteins for the treatment of infectious diseases, including HIV. Enzolytics’ flagship compound ITV-1 (Immune Therapeutic Vaccine-1) is a suspension of Inactivated Pepsin Fraction (IPF), which studies have shown is effective in the treatment of HIV/AIDS. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system.
Our plans are to test in combination the Enzolytics ITV-1 peptide in conjunction with our anti-HIV monoclonal antibodies. There is reason to believe that there will be synergistic effect achieved with this combination therapy.
As we have reported earlier, we have applications pending with the National Institute of Health (NIH) and the National Science Foundation (NSF) for further development of our anti-HIV monoclonal antibodies and our proposed production of anti-SARS-CoV-2 (CoronaVirus) antibodies. These applications are being reviewed now. Without regard to the success or lack of success of these applications, our combination of technologies with Enzolytics will provide funding for our direct progress with the precise proposals now submitted to the NIH and NSF. As outlined in detail in these applications, we will use our proprietary methodology to produce additional monoclonal antibodies against HIV that specifically target conserved, immutable sites on the virus. Recall that others, including the NIH in conjunction with Vaccine Research Center attempted for years to produce monoclonal antibodies against HIV and failed because of “virus escape” – a euphonism for the fact that their antibodies targeted a site that mutates allowing the virus to “escape” over time.
The critical nature of targeting immutable sites on the Coronavirus will be the same. I note the recent news that Eli Lilly has paused its anti-CoronaVirus monoclonal antibody trials. We are not privy to the underlying reasons for such pause, but this could be due to failure to target immutable sites on the virus or on the methodology for producing the monoclonal antibodies. When we recently asked Eli Lilly for the identity of the binding sites for its anti-CoronaVirus monoclonal antibodies, they were unable to share that information with us. The fact is that multiple neutralizing antibodies will be necessary to control the CoronaVirus, just as is the case with HIV. Our program is to produce multiple antibodies each targeting conserved, immutable sites on the virus.
As to the way we will identify the more effective epitopes (binding sites) on the CoronaVirus to target, we recognize that the structure of the Coronavirus is correlative to that of the HIV virus. Because our anti-HIV monoclonal antibodies have been proven to neutralize the HIV virus in 5 international lab testing programs, and because we know the binding site on the HIV virus to which our antibodies bind resulting in neutralization, this knowledge provides insight necessary to identifying the structure (the amino acid sequence) on the CoronaVirus we expect is at least one “Achilles Heel” of the Coronavirus. From this knowledge, a monoclonal antibody can be produced against this site that is expectedly virus neutralizing.
Additionally, we will use AI (artificial intelligence) to analyze the 16,000 known sequences of different SARS-Cov-2 viruses that have now been catalogued in the Los Alamos National Laboratory, with multiple different strains identified. By using computer analysis, several conserved (expectedly immutable and neutralizable) sites on the virus can be identified and additional monoclonal antibodies produced against these– to be used in a monoclonal antibody “cocktail”. We all have now heard of the “monoclonal antibody cocktail” administered to President Donald Trump. This is exactly what we propose – note that there are numerous different anti-SARS-Cov-2 monoclonal antibodies that can exist – some disease neutralizing and some perhaps of no benefit and some perhaps disease enhancing. Recall that the NIH and big pharma tried for 35 years to produce neutralizing antibodies against HIV and failed – notable evidence being the millions spent of the monoclonal antibodies VRC01 and VRC02 – produced by Vaccine Research Center in conjunction the NIH – both failed in trials because of “virus escape” – meaning they “targeted a site on the virus that mutates and thus the virus escapes the therapeutic effect”. The key is to produce monoclonal antibodies that target a conserved, immutable site on the virus such that the virus cannot mutate around the antibody therapeutic.
There are other pharma labs that are attempting to produce anti-CoronaVirus monoclonal antibodies. We welcome such efforts as more than one antibody can be expected to needed be provided a successful therapy. And as the virus mutates, additional anti-monoclonal antibodies will be needed.
We do however note the procedure used by other pharma companies for producing these antibodies differs significantly from ours. Other pharma companies produce “humanized” rat and mouse monoclonal antibodies where the original antibody affinity and specificity are not maintained and the chances of immunogenicity are increased. Our methodology also differs significantly from other pharma approaches using the transgenic mouse model [a human immune system which has been “grafted” within a mouse model] having been "vaccinated" with specific and selected purified CoronaVirus proteins.
In contrast, our procedure model starts with human "immune-B cells" that have been obtained from convalescent individuals who have recovered from the CoronaVirus. The primary distinction of our process for creating fully human monoclonals is the starting point is from human “immune-B cells” from humans who have survived successfully from a "natural" CoronaVirus infection. Our antibodies will retain the original natural antibody affinity and specificity, and have lower risk of immunogenicity when used as a therapeutic. They will provide broad-spectrum coverage against viral variants with increased potency, stability as a single-domain molecule, and, in the recombinant form, will have accessibility to the virus epitopes (binding sites) not accessible with a whole antibody.
We will keep you up to date on our progress. We extend our sincere appreciation for your support.
Best regards,
Charles Cotropia
CEO
BioClonetics Immunotherapeutics, Inc.
-------------------------------------------------------------
In response to the above email, I sent to Charles the following email (also dated 10/20/2020):
-------------------------------------------------------------
Hello, Mr. Cotropia.
Thank you very much for your update.
Some press releases state that BioClonetics and Enzolytics have merged into one company. One such press release is the following:
https://www.morningstar.com/news/accesswire/610379msn/enzolytics-inc-announces-execution-of-binding-letter-of-intent-for-merger-with-bioclonetics-immunotherapeutics-inc
So, have BioClonetics and Enzolytics, indeed, merged into one company? If yes, did BioClonetics buy Enzolytics, or did Enzolytics buy BioClonetics?
Also, Enzolytics is a company whose stock is being traded as an OTC (over-the-counter) stock. How will this merger (if this is a merger) affect the BioClonetics SAFEs (Simple Agreement for Future Equity) that we investors purchased on WeFunder? Will this merger cause our SAFEs to convert into actual BioClonetics stock?
Thank you.
-------------------------------------------------------------
There was no response to my email.
What is Charles Cotropia's street address?
I agree, they were part of it, but maybe they were just stupid, or got voted out of the SAGA decisions. A lot we don't know. That's why if a clever class-action suit was drawn up, pointing out the joint liability with Zhabilov, it would leave CCC at risk. I'm pretty certain Dr. Chandra and the Cotropias are tired living under the veil of constant risk.
If they do acquire ENZC in some fashion they know will work, and this new launch of Adnexus is what they say it will be, I'll forgive and move-in, so to speak. An acquisition or takeover of ENZC, which I think is their eventual play, and then retiring a couple of billion of share dilution, then merging in ENZC to Adnexus, provides complete legal protection against all of the 'chit Harry's in now, Kostiner too, for that matter. The main trash will be flushed out in any of those two scenarios. That's not a lengthy process either, if CCC does regain or acquire ENZC.
If not, sign me up for that lawsuit. I'll donate some to the cause. They'd want to come through for 2-3 reasons. Avoid legal issues with their own loyal past shareholders, acquire a stock status that does improve their bottom line, so they don't have to issue more shares out of Adnexus to cover, (as bad as that seems with the current PPS,) and if they need any ancillary work done while at ENZC, they own it once again and will have those resources.)
They also have no shy words about wanting payback, for themselves and the shareholders. There's also the question about ownership status of some of the testing and trials set up with the Strasbourg Institute and the Austrian Research group. There is some question about resuming EU patent pushing since some of that data, Harry currently owns under ENZC, would be hard to get. The Cotropias own those patents and patent applications, but some of the supporting data, if they didn't get separate copies of it, may be tied up somewhere. Those arrangements were set up under the ENZC corporate name.
IMHO.
Class Action Attorney or Personal Civil Case? Makes a huge difference who you take it to. Some of the NE lawyers you see litigating the cases against Zhabilov now, would be a great starting point. Some of them may be in NYC, NY.
There are some small-house Class Action attorneys who would go after ENZC, being a small fry organization right now, large class action firms or attorneys won't be interested. They may enjoy just shutting Harry out of ENZC, hint-hint.
CC may be willing to provide a name or two as well. A suit against Zhabilov and current co., is to his advantage too. (If he's not named in the current legal action.)
I'd be willing to donate $1K just to get such a suit filed. Make Harry respond publicly.
GLTY
Good questions all, worth answering.
For the lawsuit question, I would say, because it's a pink stock and local authorities would probably have to be involved for this kind of damages case, filing the suit in Texas saves money and avoids some issues right off the top, because only the major exchange listed stocks have Federal prosecution and reporting routes.
I'll ask Charles and Chandra if there will be some form of protection against IP stripping and removal. Since the CCC gang now owns the companies outright, to which the IP's are assigned for use and development, moving them again in a form of assigns is highly improbable. They could assign them to multiple companies for licensing agreements, but that would not remove them from where they are now, and it would not be in the best interests for the CCC gang to ever do so. If they sold their companies outright, they'd have to provide you with an equitable stock transfer and conversion to the procuring party's stock.
As you noted, they do remain privately owned, but if they ever move up to NASDAQ listing, which is a primary goal of theirs, and they then moved the IP's somewhere else again after new shareholder involvement, they'd be subject to serious prosecution, the kind of which you don't come back from, once on NASDAQ.
So, your worries, especially by prior experience are seriously justified. No denying that. I just believe for myself and a lot of others, if they do provide a shareholder remedy, and they're still hinting that this is also coming, my worry about moving the IP's again is a minor concern to me.. But your situation, I completely understand.
Have you reached out to Charles yet? I'd think with your claim, you'd get a response. Pay the $2.00 to send him a certified or registered mail to his house. title it a "Notice of Potential Legal Action" and offer him a dialogue to prevent legal hostilities. You may find out more than me about his future plans. If he only offers legal terms telling you 'sorry', I'd sure like to know about it.
My brother said he found a couple of items in your agreement to push upon, and said during their high funding days, like during their 2-year stint at Texas A&M, you'd have a claim for stock shares since "profitable" could include the significant rise in expenditures, after Charles moved those IP's into ENZC via a merger. and I assume, never put out a statement for the benefit of his start-up funders?
Also, since your investment was only $200.00, and I say that with respect, being open and willing to negotiate in step 1 of resuming this, would be seen as practicing good faith, if you ever had to go to court later. The $200.00 figure lands you in small claims court, and it would take one top wizard of an attorney to be able to collect much in the way of damages there. Getting your money back, plus say legal fees and time-damages allotted, might get you as much as $2K he said.
And since I can't read your mind, you may want that, or however many shares of Adnexus it could buy.(?)
Your call, but we'd both advise dropping him a certified letter first, move in from there.
Iam searching for a lawyer in NYNY ,I dont care what they continue to say, they had there chance .
If the Cotropia brothers own the patents for Clone 3/7 and can take those patents from one company to another (from BioClonetics to ENZC to Adnexus), then why should anyone invest into any particular company? If the Cotropias took the patents from ENZC, what is to stop them from taking the patents from the next company?
I think that the Cotropias are hoping that the ENZC shareholders (including those who originally invested into BioClonetics) will just keep talking and complaining on message boards and will not take any legal actions.
By the way, if an ENZC shareholder wants to sue the Cotropias, should that shareholder get a lawyer in Texas (the Cotropias' home state) or a lawyer in the shareholder's home state?
Doc why would he come thru ? They ran enzc into the ground ,you may say it was others BUT he was part of it ! I have invested and lost more than I should have ,I have NO intention of investing in CCC nor have any money to do so.
Three things about the Adnexus Biotech website, which I hope becomes the new ENZC website by acquisition of ENZC:
(1) The new management team has a lot of large biopharma experience, and checking up on them corroborates that.
(2) Patent Trackers and Milestone Trackers are in place for all IP's and development. They're promising to keep those updated in real-time.
(3) There is 'some' published data here, not enough current stuff, but leagues ahead of where ENZC ever sat. Fraud, Scam or the Holy Grail, it's a much more believable and smart website. They put some time, marketing smarts and web specialists in on this one. I know, we just did the same thing for our website that launches tomorrow, and is searchable 1 week later as we change the DNS nameservers over to the new hosting company.
The 'feel' is much more legit. I don't have anything else to say, just that. I hope CCC comes through for us ENZC bag-holders.
It appears the Adnexus Biotech website has fully launched, some content and published data have been updated from last week. There is no mention of the go-public date and no 'investors page' at this time, but Chandra did state that is coming very soon. We'll see. The website sure reads a damn-sight better than ENZC's ever did, providing laymen-to-expert messaging on their proposed treatment/cures and AI expansion.
My letter to Cotropia is sent off, my calls to Dr. Chandra prepped. If CCC does not come up with an ENZC shareholder remedy soon, they'll still be as guilty as Zhabilov, and all of this is for naught. If they do come through, I'll be offering my company's services to them at cost, help them move along. Maybe being part of a solution will be better than just investing from the sidelines. Who knows? In any case, increased communications and transparency go a long way to assuring investor's confidence, not to mention future healthcare customers.
Our place just deployed a new type of AI tech that actually works better for a lot of what we do. First time an AI tech really proved itself in our industry. Maybe I'll have more common ground to chat with Chandra now that we've got the top new AI in the data and document processing field.
GLTA
The ITV-1 has been pumped since 1996 - why hasn't it been approved by the US or any other country.
Why hasn't ENZC done any FDA approved clinical trials?
Sagaliam is dead - delisted from Nasdaq and still hasn't been listed on OTC. SAGA is broke - no capital to do anything.
I love the Bulgarian nonsense.
IG
If this is Sharabura doing these PR's (?) He needs to return his college degree. Bad exec, bad liar, weak-@$$ strategist.
I believe Sharabura or someone at ENZC, maybe even an MM they like to work with, is pumping in a few hundred here and there, and then selling off from a cash account so they can keep doing it without penalty.
Their PR's are a huge amount of lying BS, and they have folks all over their Twitter/X and Google pages saying so. I think they're manipulating their own shares to show volume and volatility, trying to get new penny investors to buy in.
Nothing but a self-engineered pump in a company whose best effort is to announce another "Letter of Understanding" with another Bulgarian (gag) company. Totally non-binding, no-obligation nonsense only a 2nd-grader may be fooled by.
Retail day-traders are probably getting sucked in to some point, but most know ENZC's mess and won't even recommend them as a day-trade to their customers. I know, I just checked with two I used to work with. The word is out on ENZC. If they don't change management and put out some really significant info, even day-trading online services won't recommend them anymore.
GLTY
Hello, docsetc.
In your most recent response to me, you said that you and your brother, a lawyer, wanted to see the agreement that I had signed to invest into BioClonetics.
Well, the agreement appears at the following link:
https://www.sec.gov/Archives/edgar/data/1701251/000167025417000251/document_3.pdf
My purchase amount is $200.
When I invested into BioClonetics, BioClonetics was NOT an OTC stock. BioClonetics was not being sold on any exchange.
Also, the above agreement does not explicitly mention any BioClonetics technologies. There is no mention of Clone 3.
Thanks.
Ding ding ding!
X.was.a.reality.look,into.good.planning.reading.inage./a.compet'.contract.has,a big profit.margin/.itv-1./.. Re:.ppl.now buying.at.bottom with much more shares for the money are also getting the dividend #'shares greatly increased.. to the level of possibly having a thousand shares given.
At the same time as life goes its assumed there will be an effort to get some price lowered. .Doing this has little effect and its noticed to have absolutely none except to to get a notice of a distraction.
The ppl are buying for good reasons and many are those that left and want the good bottom price.Many are thinking of the opportunity at hand like business people do. They are not thinking in the way to of a put down which requires no business acumen
They will in the future be the ppl that will remember the wisdom in buying in the 00's.and some reading here will get - it and get in..now
When it's going
Remember Savov he is under a contract already and will sell itv-1 during the appeal wait and he has no chance. See his profit planning in what he has written..it is enormous..
All the lies posted on X from Shabura apparently are working. More sucker or clueless buyers are buying up ENZC shares.
Harry and the dirty four are fattening up their ENZC cash cow or ATM machine. ... Wait till Harry or his wife or other member of the dirty four cash out money from the ATM machine, PPS will drop.
I wonder how long ENZC has been operating like this the last four to five years. We shareholders have been paying for house (mansion) mortgages for Charles , Chandra, Harry and other members of ENZC.
So much of one life saving has gone to pay for these crooks mortgages and expensive cars !
They can keep publishing BS/ or whatever, they can pump this as a scam, I don't care as long as they pump it to about 5 or 10 cents so I can sell it and get the hell out.
Independent Valuation Report Pre Clinical Studies
Investments
___________________________________________________________________________________
Press Release July 20-2021
Enzolytics Announces the Signing of a Letter of Intent with Creative Biolabs, Inc.
for Licensing and Commercialization of anti-HTLV-1 Monoclonal Antibodies
https://www.creative-biolabs.com/
https://finance.yahoo.com/news/enzolytics-announces-signing-letter-intent-113000339.htm
________________________________________
Press release July 21-2021
Enzolytics and Lonza Bioscience Combine Technologies to Fast-track Development and
Production of Anti-HIV and Anti-SARS-CoV-2 Monoclonal Antibodies produced by Enzolytics
https://www.lonza.com/
https://www.bloomberg.com/press-releases/2021-07-21/enzolytics-and-lonza-bioscience-combine-technologies-to-fast-track-development-and-production-of-anti-hiv-and-anti-sar
_________________________________________
July 22 INTERVIEW
with
James Hicks, Charles Cotropia and Gurav Chandra
http://www.youtube.com/watch?v=mdljO9VLgj0
______________________________________________________________
COLLEGE STATION, TX August 25, 2021
Important Excerpt from this news progress update.
>>>>>><<<<<<
"The monoclonal antibodies being produced by Enzolytics against the CoronaVirus target 19 conserved immutable sites on the virus, sites which the Company has now confirmed are conserved sites not only on the initial virus strains but also existing in the Delta and Lambda variants, as well as in the Alpha, Beta and Gamma variants."
Enzolytics Inc. and Samsung Biologics Announce
Development and Manufacturing Agreement for Anti-
HIV and Anti-SARS-CoV-2
Important Excerpt from this news progress update.
>>>>>><<<<<<
"Samsung Biologics (KRX: 207940. K.S.), a leading contract development and manufacturing organization and Enzolytics (ENZC), a drug development company committed to commercializing multiple proprietary therapeutics to treat debilitating infectious diseases, announced the signing of a strategic CDMO partnership agreement."_______
2000 North Central Expressway
Plano, TX 75074
972-292-9414
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |